SOTERA HEALTH COMPANY Selling, General and Administrative Expense
SOTERA HEALTH COMPANY (SHC) reported Selling, General and Administrative Expense of $68.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- SOTERA HEALTH COMPANY selling, general and administrative expense for the quarter ending 2026-06-30 was $68.16M, a 1.07% decline year-over-year.
- SOTERA HEALTH COMPANY selling, general and administrative expense for the quarter ending 2026-03-31 was $68.21M, a 8.17% increase year-over-year.
- SOTERA HEALTH COMPANY selling, general and administrative expense for the quarter ending 2025-12-31 was $57.51M, a 6.99% decline year-over-year.
- SOTERA HEALTH COMPANY selling, general and administrative expense for the quarter ending 2025-09-30 was $63.29M, a 2.07% increase year-over-year.
- SOTERA HEALTH COMPANY selling, general and administrative expense for fiscal 2025 was $252.76M, a 4.18% increase from fiscal 2024.
- SOTERA HEALTH COMPANY selling, general and administrative expense for fiscal 2024 was $242.63M, a 2.52% increase from fiscal 2023.
- SOTERA HEALTH COMPANY selling, general and administrative expense for fiscal 2023 was $236.67M, a 3.68% decline from fiscal 2022.
- SOTERA HEALTH COMPANY selling, general and administrative expense for fiscal 2022 was $245.71M, a 24.00% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.16M 10-Q · filed 2026-08-06 | $136.37M 10-Q · filed 2026-08-06 | $193.88M derived: sum of 3 quarters · filed 2026-08-06 | $257.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $68.21M 10-Q · filed 2026-05-05 | $125.72M derived: sum of 2 quarters · filed 2026-05-05 | $189.02M derived: sum of 3 quarters · filed 2026-05-05 | $257.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $57.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $120.81M derived: sum of 2 quarters · filed 2026-02-24 | $189.70M derived: sum of 3 quarters · filed 2026-08-06 | $252.76M 10-K · filed 2026-02-24 |
| 2025-09-30 | $63.29M 10-Q · filed 2025-11-04 | $132.19M derived: sum of 2 quarters · filed 2026-08-06 | $195.25M 10-Q · filed 2025-11-04 | $257.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $68.89M 10-Q · filed 2026-08-06 | $131.95M 10-Q · filed 2026-08-06 | $193.79M derived: sum of 3 quarters · filed 2026-08-06 | $255.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $63.06M 10-Q · filed 2026-05-05 | $124.90M derived: sum of 2 quarters · filed 2026-05-05 | $186.91M derived: sum of 3 quarters · filed 2026-05-05 | $247.48M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $61.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $123.85M derived: sum of 2 quarters · filed 2026-02-24 | $184.42M derived: sum of 3 quarters · filed 2026-02-24 | $242.63M 10-K · filed 2026-02-24 |
| 2024-09-30 | $62.01M 10-Q · filed 2025-11-04 | $122.58M derived: sum of 2 quarters · filed 2025-11-04 | $180.79M 10-Q · filed 2025-11-04 | $241.15M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $60.58M 10-Q · filed 2025-08-08 | $118.78M 10-Q · filed 2025-08-08 | $179.14M derived: sum of 3 quarters · filed 2026-02-24 | $233.25M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $58.21M 10-Q · filed 2025-05-01 | $118.57M derived: sum of 2 quarters · filed 2026-02-24 | $172.68M derived: sum of 3 quarters · filed 2026-02-24 | $232.97M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $60.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $114.47M derived: sum of 2 quarters · filed 2026-02-24 | $174.76M derived: sum of 3 quarters · filed 2026-02-24 | $236.67M 10-K · filed 2026-02-24 |
| 2023-09-30 | $54.11M 10-Q · filed 2024-11-05 | $114.40M derived: sum of 2 quarters · filed 2024-11-05 | $176.31M 10-Q · filed 2024-11-05 | $242.26M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $60.29M 10-Q · filed 2024-08-05 | $122.20M 10-Q · filed 2024-08-05 | $188.15M derived: sum of 3 quarters · filed 2025-02-27 | $245.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $61.91M 10-Q · filed 2024-05-02 | $127.86M derived: sum of 2 quarters · filed 2025-02-27 | $184.95M derived: sum of 3 quarters · filed 2025-02-27 | $248.08M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $65.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $123.04M derived: sum of 2 quarters · filed 2025-02-27 | $186.17M derived: sum of 3 quarters · filed 2025-02-27 | $245.71M 10-K · filed 2025-02-27 |
| 2022-09-30 | $57.09M 10-Q · filed 2023-11-01 | $120.22M derived: sum of 2 quarters · filed 2023-11-01 | $179.76M 10-Q · filed 2023-11-01 | $231.59M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $63.13M 10-Q · filed 2023-08-03 | $122.67M 10-Q · filed 2023-08-03 | $174.50M derived: sum of 3 quarters · filed 2024-02-27 | $218.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $59.54M 10-Q · filed 2023-05-03 | $111.37M derived: sum of 2 quarters · filed 2024-02-27 | $155.41M derived: sum of 3 quarters · filed 2024-02-27 | $205.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $51.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $95.86M derived: sum of 2 quarters · filed 2024-02-27 | $145.69M derived: sum of 3 quarters · filed 2024-02-27 | $198.16M 10-K · filed 2024-02-27 |
| 2021-09-30 | $44.04M 10-Q · filed 2022-11-02 | $93.87M derived: sum of 2 quarters · filed 2022-11-02 | $146.33M 10-Q · filed 2022-11-02 | $199.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $49.83M 10-Q · filed 2022-08-04 | $102.29M 10-Q · filed 2022-08-04 | $155.45M derived: sum of 3 quarters · filed 2023-02-28 | $201.08M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $52.47M 10-Q · filed 2022-05-05 | $105.62M derived: sum of 2 quarters · filed 2023-02-28 | $151.25M derived: sum of 3 quarters · filed 2023-02-28 | $193.94M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $53.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $98.79M derived: sum of 2 quarters · filed 2023-02-28 | $141.47M derived: sum of 3 quarters · filed 2023-02-28 | $178.53M 10-K · filed 2023-02-28 |
| 2020-09-30 | $45.63M 10-Q · filed 2021-11-10 | $88.32M derived: sum of 2 quarters · filed 2021-11-10 | $125.37M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $42.68M 10-Q · filed 2021-08-12 | $79.74M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $37.05M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $147.48M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |